JP2021518389A5 - - Google Patents
Info
- Publication number
- JP2021518389A5 JP2021518389A5 JP2020550632A JP2020550632A JP2021518389A5 JP 2021518389 A5 JP2021518389 A5 JP 2021518389A5 JP 2020550632 A JP2020550632 A JP 2020550632A JP 2020550632 A JP2020550632 A JP 2020550632A JP 2021518389 A5 JP2021518389 A5 JP 2021518389A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646432P | 2018-03-22 | 2018-03-22 | |
| US62/646,432 | 2018-03-22 | ||
| PCT/US2019/023111 WO2019183186A1 (en) | 2018-03-22 | 2019-03-20 | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518389A JP2021518389A (ja) | 2021-08-02 |
| JP2021518389A5 true JP2021518389A5 (https=) | 2022-03-31 |
| JP7485609B2 JP7485609B2 (ja) | 2024-05-16 |
Family
ID=66001366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550632A Active JP7485609B2 (ja) | 2018-03-22 | 2019-03-20 | ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11597721B2 (https=) |
| EP (1) | EP3768667B1 (https=) |
| JP (1) | JP7485609B2 (https=) |
| KR (1) | KR102741437B1 (https=) |
| CN (1) | CN111936486B (https=) |
| ES (1) | ES2944733T3 (https=) |
| WO (1) | WO2019183186A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| SMT202400185T1 (it) * | 2020-03-11 | 2024-07-09 | Beijing Innocare Pharma Tech Co Ltd | Composti eterociclici per inibire attività di tyk2 |
| AU2021254764A1 (en) | 2020-04-14 | 2022-11-03 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CA3213816A1 (en) | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| WO2022206705A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| TWI804266B (zh) * | 2021-04-07 | 2023-06-01 | 大陸商上海齊魯製藥研究中心有限公司 | Tyk2抑制劑及其用途 |
| JP7740849B2 (ja) * | 2021-05-04 | 2025-09-17 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | 含窒素複素環ピリジン化合物 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| CA3223641A1 (en) * | 2021-06-22 | 2022-12-29 | Wenyuan Qian | Sulfoximine compound and use thereof |
| JP2024535865A (ja) * | 2021-07-15 | 2024-10-02 | メッドシャイン ディスカバリー インコーポレイテッド | 硫黄／リン含有アリール系化合物及びその使用 |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| WO2023064223A1 (en) | 2021-10-11 | 2023-04-20 | Gossamer Bio Services, Inc. | Tri-substituted pyridines |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| AU2022412835A1 (en) | 2021-12-16 | 2024-06-20 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| WO2024020221A1 (en) * | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| CN120239699A (zh) * | 2022-12-22 | 2025-07-01 | 祐森健恒生物医药（上海）有限公司 | 一种吡啶多取代化合物的盐型、晶型及其制备方法 |
| CN120607493B (zh) * | 2025-06-04 | 2026-04-24 | 江西科技师范大学 | 一种含嘧啶结构的酰胺类化合物及其在制备tyk2 jh2激酶抑制剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2763975B1 (en) * | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CN104159891B (zh) * | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| KR102233252B1 (ko) * | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| AR110351A1 (es) | 2016-12-13 | 2019-03-20 | Bristol Myers Squibb Co | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
-
2019
- 2019-03-20 CN CN201980020946.5A patent/CN111936486B/zh active Active
- 2019-03-20 WO PCT/US2019/023111 patent/WO2019183186A1/en not_active Ceased
- 2019-03-20 US US16/982,937 patent/US11597721B2/en active Active
- 2019-03-20 EP EP19715330.7A patent/EP3768667B1/en active Active
- 2019-03-20 JP JP2020550632A patent/JP7485609B2/ja active Active
- 2019-03-20 ES ES19715330T patent/ES2944733T3/es active Active
- 2019-03-20 KR KR1020207029906A patent/KR102741437B1/ko active Active